

**REMARKS**

Favorable reconsideration is respectfully requested in view of the foregoing amendments and the following remarks.

**I. CLAIM STATUS AND AMENDMENTS**

Claims 1-5 are pending in this application and stand rejected.

Claim 1 has been amended to clarify that miniplasmin is reacted with the substrate virus. Support for this can be found in the specification, for example, at page 4, lines 9-11, page 6, lines 5-24 and in original claims 2-3. Therefore, no new matter has been added by this amendment.

**II. ADVISORY ACTION**

In item 3 of the Advisory Action, it is indicated that “viral envelope fusion protein” in claim 1 (added in the after final response of February 25, 2005) reads on a chimeric fusion protein, and not a whole virus or the fusion protein subunits as used in the claims. It is further indicated that this language is new matter, and if it is intended as fusion protein subunits, it raises enablement and written description issues. It is respectfully submitted that the present amendment overcomes these concerns for reasons which are self-evident.

Furthermore, it is respectfully submitted that the indefiniteness rejection and the obviousness rejection are overcome for the reasons set forth in sections II-III on pages 4-7 of the after final response.

Attorney Docket No. 2002\_0319A  
Serial No. 10/070,921  
July 13, 2005

**CONCLUSION**

In view of the foregoing amendments and remarks, the present application is in condition for allowance and early notice to that effect is hereby requested.

If the Examiner has any comments or proposals for expediting prosecution in this application, the Examiner is invited to contact the undersigned attorney directly at the telephone number below.

Respectfully submitted,

Hiroshi KIDO et al.

By:

  
Jay F. Williams

Registration No. 48,036

Attorney for Applicants

MRD/JFW/akl  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
July 13, 2005